Who Paid My Doc
myRisk
Device Germline Dna Sequencing Hereditary Cancer And Rearrangement Analysis
General payments
$404,515
Research payments
$113,880
Through program year 2022, $404,515 in general payments and $113,880 in research payments were reported against myRisk (Germline Dna Sequencing Hereditary Cancer And Rearrangement Analysis).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | General | $215,727 | 2,728 |
| 2022 | Research | $113,880 | 3 |
| 2021 | General | $188,788 | 2,891 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2022.
The top 5 of 64 specialties; each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.
The top 5 of 47 states; each share is of general payments naming this product in 2022 where a state was reported.
Records
5,619 general · 3 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.